Med Res Rev (2022) 42(1):576614
For Crohn's patients, understanding your genetic predisposition to GLP-1 efficacy helps prescribers determine whether the expected benefit justifies gastrointestinal risks specific to your condition
This blog covers a recent Renegade Research Roundtable, two studies reporting on the effects of GLP-1 agonists on people with mast cell activation syndrome (MCAS) and intracranial hypertension, and two major GLP-1 long-COVID trials getting underway
Applied Biosystems, Foster City, CA, USA) using gene expression assays and Universal PCR Master Mix (TaqMan
Across the SLD spectrum, GLP-1 RAs demonstrated modest but directionally consistent improvements in liver enzyme profiles (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), with 4 of the 7 ALT outcome estimates showing significant reductions, and 4 of the 9 AST outcome estimates showing significant reductions
Multivitamins, Multimineral & Antioxidants